Using the PD-L1 inhibitor durvalumab with neoadjuvant cisplatin/gemcitabine chemotherapy and continuing using it as adjuvant therapy after radical surgery could achieve high rates of event-free survival and downstaging, new findings show.
Neoadjuvant immunotherapy is an attractive alternative to chemotherapy for patients with localized MIBC because of its lower toxicity profile.
Patient comorbidities were among the significant risk factors for kidney function decline.
Investigators report findings from a retrospective study of 13,081 patients undergoing radical cystectomy.
In a study, women with muscle-invasive bladder cancer were likely to have adverse molecular profiles.
Trimodality therapy produces similar oncologic outcomes as radical cystectomy in patients with muscle-invasive bladder cancer, a new study suggests.
5α-reductase inhibitors are widely used to treat lower urinary tract symptoms in men with benign prostatic hyperplasia (BPH).
The optimal duration of antibiotic prophylaxis is still unknown.
Study findings suggest that chemoradiation therapy could be considered an alternative to surgery in this patient population.
Extended vs standard lymph node dissection offers no advantage in terms of time to progression and overall survival, but does lower the risk of death from bladder cancer.
